Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Other Non-Current Liabilities: 2011-2024

Historic Other Non-Current Liabilities for Ani Pharmaceuticals (ANIP) over the last 9 years, with Dec 2024 value amounting to $19.8 million.

  • Ani Pharmaceuticals' Other Non-Current Liabilities fell 43.60% to $11.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year decrease of 43.60%. This contributed to the annual value of $19.8 million for FY2024, which is 17.40% down from last year.
  • Per Ani Pharmaceuticals' latest filing, its Other Non-Current Liabilities stood at $19.8 million for FY2024, which was down 17.40% from $24.0 million recorded in FY2023.
  • Over the past 5 years, Ani Pharmaceuticals' Other Non-Current Liabilities peaked at $35.1 million during FY2022, and registered a low of $14.5 million during FY2020.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $24.0 million (2023), whereas its average is $26.3 million.
  • Per our database at Business Quant, Ani Pharmaceuticals' Other Non-Current Liabilities soared by 114.06% in 2021 and then tumbled by 31.54% in 2023.
  • Ani Pharmaceuticals' Other Non-Current Liabilities (Yearly) stood at $14.5 million in 2020, then surged by 114.06% to $31.0 million in 2021, then grew by 13.09% to $35.1 million in 2022, then plummeted by 31.54% to $24.0 million in 2023, then fell by 17.40% to $19.8 million in 2024.